Abstract
Background: Orthopaedic surgery patients have long been recognized to be at increased risk of venous thromboembolism (VTE). VTE is a significant cause of mortality, long-term disability and chronic ill-health. VTE is considered internationally to be a silent killer with fewer than 1 in 10 fatal cases of pulmonary embolism diagnosed before death. In the UK, the cost of treating non-fatal symptomatic VTE and associated long-term disability is around £640 million per year.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
